Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Brilinta, expanded indication, long-term use, FDA

Brilinta image courtesy of AstraZeneca

Technology | Antiplatelet and Anticoagulation Therapies | September 15, 2015
September 15, 2015 — AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved Brilinta (...
New Haven Pharmaceuticals, FDA approval, Durlaza, antiplatelet, once-daily, extended-release
Technology | Antiplatelet and Anticoagulation Therapies | September 11, 2015
September 11, 2015 — New Haven Pharmaceuticals Inc. announced U.S. Food and Drug Administration (FDA) approval of...
News | Antiplatelet and Anticoagulation Therapies | September 08, 2015
September 8, 2015 — Extending clot-preventing dual antiplatelet therapy (DAPT) beyond the recommended 12 months after...
Xarelto, PMSS, XANTUS, ESC 2015, major bleeding, non-valvular atrial fibrillation, NVAF
News | Antiplatelet and Anticoagulation Therapies | September 04, 2015
September 4, 2015 — Janssen Pharmaceuticals Inc. and its development partner Bayer HealthCare announced results from...
bivalirudin,angiomax
Feature | Antiplatelet and Anticoagulation Therapies | September 01, 2015
September 1, 2015 — Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of...
News | Cath Lab | August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report...
Boehringer Ingelheim, RE-DUAL PCI, RE-CIRCUIT, Pradaxa, first U.S. patients,
News | Antiplatelet and Anticoagulation Therapies | August 05, 2015
August 5, 2015 — Boehringer Ingelheim announced the first U.S. patients have been enrolled in two of the company's...
triple therapy, dual antiplatelet therapy, atrial fibrillation, heart attack, older patients, JACC
News | Antiplatelet and Anticoagulation Therapies | August 04, 2015
August 4, 2015 — Triple therapy is no better than dual antiplatelet therapy in preventing major adverse cardiac events...
The Medicines Company, bivalirudin, Angiomax, litigation, Hospira Inc.
News | Cath Lab | July 22, 2015
July 22, 2015 — The Medicines Company announced the U.S. Court of Appeals for the Federal Circuit Court has ruled...
Xarelto, anticoagulant protocol, discharge, outcomes, DVT, PE
News | Antiplatelet and Anticoagulation Therapies | July 21, 2015
July 21, 2015 "” Two companion papers published in Academic Emergency Medicine  address the question of when it is...
platelet-like particles, PLPs, clotting, substitute, Carver, Lyon, NIBIB

Cartoon representation of a deformable platelet-like particle with fibrin nanobodies attached

Feature | Antiplatelet and Anticoagulation Therapies | July 13, 2015
July 13, 2015 - Researchers have created tiny gel particles that can perform the same essential functions as platelets...
idarucizumab, dabigatran, anticoagulant, Boehringer Ingelheim, RE-VERSE AD
News | Antiplatelet and Anticoagulation Therapies | July 07, 2015
July 7, 2015 - Results from an interim analysis of the Phase III RE-VERSE AD patient study demonstrate that 5 g of...
cangrelor, Kangreal, FDA approval, The Medicines Company, antiplatelet agent
Technology | June 22, 2015
June 22, 2015 - The Medicines Company announced the approval of cangrelor (Kengreal) by the U.S. Food and Drug...
VHA, dabigatran, patient adherence, JAMA, Mintu Turakhia
News | Antiplatelet and Anticoagulation Therapies | June 18, 2015
June 18, 2015 - Atrial fibrillation patients on the anticoagulant dabigatran were more likely to adhere to the...
News | Antiplatelet and Anticoagulation Therapies | June 11, 2015
June 11, 2015 - Patients who received a bare metal coronary stent did not display significant differences in rates of...